Senisca

RNA splicing, senotherapeutics, oligonucleotides

modulatingrna therapeutic

senisca.com·Exeter, United Kingdom·Seed

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-AQQM

Projects

Alternative splicing reversal of cellular senescence in aesthetic aging

exploratory

research program · medium

Investigate whether targeting alternative splicing can reverse cellular senescence in the context of aesthetic aging and skin aging.

Research program focused on dysregulated mRNA processing, alternative splicing, senomorphic effects, and oligonucleotide therapeutics for manipulation of disrupted mRNA processing.

2021 publications listed on the company site and in PubMed discussing alternative splicing and senotherapeutic approaches for aesthetic aging and skincare.

The supplied publication abstract describes cellular senescence as a driver of skin aging and identifies dysregulated mRNA processing as a targetable aging hallmark, with oligonucleotide therapeutics proposed as a modality; no product or clinical efficacy data are provided.

RNA senotherapeutics platform

preclinical

platform · high

Develop oligonucleotide-based therapeutics that modulate RNA biology to reprogram senescent cells, reset splicing factor levels, and address causes of age-related disease.

RNA splicing modulation using oligonucleotide-based senotherapeutic approaches targeting dysregulated mRNA processing in senescent cells.

Seed-funded development of RNA senotherapeutics, including a reported £3.7 million seed funding round in 2023.

Company materials state that founders identified dysregulated RNA splicing as a druggable hallmark of ageing and are developing oligonucleotide approaches to reverse cellular senescence; no clinical results are provided.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence